Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK3280 in Idiopathic Pulmonary Fibrosis (IPF)
NCT07719023Phase 3Not yet recruiting
- Sponsor
- Ark Biosciences
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of AK3280 in idiopathic pulmonary fibrosis (IPF), sponsored by Ark Biosciences. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
AK3280
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07719023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719023.